<DOC>
	<DOC>NCT00158379</DOC>
	<brief_summary>Time to progression (physical examination and radiologic imaging</brief_summary>
	<brief_title>Taxol Carboplatin and Erythropoetin</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>patients with primary ovarian cancer ECOG 02 Age &gt;= 18 no chemotherapy, radiation or immunotherapy in medical history for ovarian cancer adequate bone marrow, liver and kidney reserve: leukocytes ≥ 2.0 x 109/l, platelets ≥ 100 x 109/l, bilirubin &lt;= 2,0 mg%, creatinine &lt;= 1,5 mg% or creatinine clearance ≥ 60 ml/ min, hemoglobin ≥ 9 g/ dl SGOT, SGPT an AP within 3 fold of the reference laboratory's normal range written informed consent beforeexisting heart illness, Cardiac infarct within last 6 months Radiotherapy within 4 weeks for study entry Patients in pregnancy or breast feeding (in premenopausal women anticonception has to be assured: intrauterine devices, surgical methods of sterilization, or, in hormone insensitive tumors only, oral, subcutaneous or transvaginal hormonal, nonestrogen containing contraceptives)</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>